Company Overview

Prescient Therapeutics is an ASX-listed (ASX: PTX) clinical stage oncology company developing novel drugs to treat a range of challenging cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.

These unique drugs (PTX-200 and PTX-100) have impeccable scientific pedigree from prestigious US institutions and are underpinned by a vast body of published research.

With compelling proof of concept and safety data established, Prescient is now conducting trials in breast cancer, ovarian cancer and Acute Myeloid Leukemia (AML) for PTX-200 and is planning a transformative trial in several cancers for PTX-100.

Investment Highlights

• Multiple shots on goal with two novel personalized cancer therapies in multiple trials
• One of deepest clinical pipelines on the ASX
• Funded through to value-accrative catalysts, with a fantastic share register
• Great scientific and clinical team with a proven record of success
• Transformative opportunity in rare blood cancers
• Multiple catalysts this year
• Following in the footsteps of US targeted therapy companies that have enjoyed spectacular success

Clinical Pipeline

Prescient is currently conducting several clinical trials in the US, at world renowned US cancer centres. All programs are clinical stage, with the risk and timelines of typical pre-clinical programs now behind it.
Role of PTX-200 & PTX-100

Both PTX-200 and PTX-100 work by inhibiting the survival pathways of growth molecules, specifically AKT (PTX-200) and Ras (PTX-100) that play a key role in the development and evolution of cancerous cells.

Prescient’s drugs block the AKT & Ras growth signals, switching the growth signals off and causing the cancer cell to die.

AKT & Ras are growth switches found in cancer cells - when they are turned on, they send a signal to the cancer cell to grow.

Market Benchmarks: Blue Sky Ahead for PTX

Prescient Therapeutics is operating in a space which has already attracted the attention of billion dollar companies, including US$3.41 billion-capped (A$4.37B) Loxo Oncology Inc. (NASDAQ:LOXO) and the US$3.79 billion capped Blueprint Medicines Corp (NASDAQ:BPMC).

An overview of the comparative market valuations of the $12.8 million capped Prescient (ASX:PTX) and its peers suggests some significant mispricing, with Prescient identifying several transformative milestones that could have significant market impact.

Disease Areas/Program Overview

PTX-200

Breast Cancer: PTX is developing PTX-200 as a treatment for HER2+ breast cancer – which accounts for about 80% of breast cancers, and where there is still a strong unmet need for new treatments. The Phase 1b trial was successfully completed, meeting its safety endpoints. Final efficacy data from this trial is due out shortly. This trial is now in Phase 2. AML is a type of cancer that affects blood and bone marrow. The incidence of this cancer has increased by 50% since 2013 in the US alone, yet treatment has barely changed in 40 years. This is an area of high interest for clinicians and investors. A successful Phase 1 trial has been completed and a Phase 1b trial is currently underway. The trial is led by world-leading authority in AML, Professor Jeff Lancet, who led Celator’s transformative AML trial that led to its US$1.5 billion acquisition by Jazz Pharmaceuticals. PTX-200 has been granted orphan drug status by the FDA for use in AML, which delivers benefits such as lower cost of development; possible acceleration of approval timelines; and guaranteed 7 years of market exclusivity upon approval.

Ovarian Cancer is one of the most common cancers in women. Chemotherapy has been the standard of care for decades. While initially effective, almost all patients relapse and become resistant to chemotherapy. PTX-200 is being targeted as a treatment for relapsed and chemo-resistant patients, and is currently in a Phase 1b trial.

PTX-100

PTX-100 is a first in class drug candidate that has previously completed a Phase 1 trial in advanced solid tumours, where it demonstrated safety and disease stabilization.

Rare Haematological Cancers: The role of certain mutations in the Ras pathway in certain rare blood cancers has only recently been discovered. PTX-100 has a strong competitive advantage and significant head start in this field, as the first drug candidate in the clinic that addresses this mutation. A clinical trial is planned in several cancers, which has the potential to be a major opportunity for Prescient.